Cell and Gene Therapy for Personalised Medicine (CGT4PM2027)
Cell and Gene Therapy for Personalised Medicine (CGT4PM2027) supports multinational research teams developing and validating novel cell and gene therapies to improve health outcomes.
Funder: Austrian Science Fund (FWF)
Due Dates: January 20, 2027, 2:00 pm CET (Pre-proposal) | May 25, 2027, 2:00 pm CEST (Full proposal)
Funding Amounts: Approximately €33 million total call budget
Summary: Supports multinational research developing and validating innovative cell and gene therapies for personalised medicine across all disease areas.
Key Information: Partners must meet their national or regional funder’s eligibility rules; Austrian applicants also submit administrative and financial data to FWF.
Description
CGT4PM2027 is the fourth joint transnational call of the European Partnership for Personalised Medicine (EP PerMed). It funds innovative human-health research developing and validating novel cell and gene therapies for personalised medicine, with projects in all disease areas encouraged. Supported approaches include somatic cell therapeutics, gene therapeutics, combined cell-and-gene therapeutics, and novel biological products such as mRNA, other nucleic acid-based methods, and extracellular vesicles used as vehicles for gene-based therapeutic procedures.
The call brings together academic, clinical/public health, and private research teams across countries. It encourages interdisciplinary and cross-sector collaboration, including patient organisations, regulatory and health technology assessment agencies, and end-user perspectives. Its broader goal is improved health outcomes within sustainable healthcare systems. The Joint Call Secretariat is hosted by France’s ANR; Austrian funding is provided through FWF and Fonds Zukunft Österreich, with European Union co-funding.
